Indivior PLC (NASDAQ:INDV) Short Interest Up 9.9% in December

Indivior PLC (NASDAQ:INDV) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 1,220,000 shares, a growth of 9.9% from the December 15th total of 1,110,000 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average trading volume of 1,280,000 shares, the short-interest ratio is presently 1.0 days.

Institutional Investors Weigh In On Indivior

Several hedge funds and other institutional investors have recently modified their holdings of INDV. Iron Triangle Partners LP bought a new position in shares of Indivior during the third quarter worth about $8,243,000. Krensavage Asset Management LLC acquired a new position in shares of Indivior in the 3rd quarter valued at about $6,843,000. Millennium Management LLC grew its position in shares of Indivior by 48.1% during the 2nd quarter. Millennium Management LLC now owns 493,313 shares of the company’s stock valued at $7,952,000 after buying an additional 160,282 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in Indivior during the third quarter worth about $2,632,000. Finally, Clark Estates Inc. NY bought a new position in Indivior in the third quarter worth about $2,477,000. Institutional investors own 60.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on INDV shares. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price target (up from $15.00) on shares of Indivior in a research report on Friday, October 25th. Craig Hallum lowered their target price on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, October 11th.

Indivior Price Performance

Indivior stock opened at $11.65 on Monday. Indivior has a 12-month low of $7.33 and a 12-month high of $23.22. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -291.18 and a beta of 0.74. The firm’s fifty day moving average price is $11.46 and its 200 day moving average price is $11.04.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. The business had revenue of $307.00 million for the quarter, compared to analysts’ expectations of $302.25 million. Analysts forecast that Indivior will post 1.62 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.